Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy.
Ando Y, Hayashi T, Ito K, Suzuki E, Mine N, Miyamoto A, Oya M, Matsuda H, Isaji A, Nakanishi T, Imaizumi K, Shibata T, Okada T, Sakurai K, Naito K, Uyama I, Kawada K, Takahashi H, Yamada S. Ando Y, et al. Among authors: ito k. Support Care Cancer. 2016 Feb;24(2):871-878. doi: 10.1007/s00520-015-2856-9. Epub 2015 Jul 25. Support Care Cancer. 2016. PMID: 26206077 Free PMC article. Clinical Trial.
Effect of renal function on pemetrexed-induced haematotoxicity.
Ando Y, Hayashi T, Ujita M, Murai S, Ohta H, Ito K, Yamaguchi T, Funatsu M, Ikeda Y, Imaizumi K, Kawada K, Yasuda K, Yamada S. Ando Y, et al. Among authors: ito k. Cancer Chemother Pharmacol. 2016 Jul;78(1):183-9. doi: 10.1007/s00280-016-3078-7. Epub 2016 Jun 10. Cancer Chemother Pharmacol. 2016. PMID: 27286996 Free PMC article.
Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphoma.
Tomono A, Ito K, Hayashi T, Ando M, Ando Y, Tsuge M, Okamoto A, Inaguma Y, Okamoto M, Emi N, Yamada S. Tomono A, et al. Among authors: ito k. Cancer Chemother Pharmacol. 2016 Aug;78(2):305-12. doi: 10.1007/s00280-016-3076-9. Epub 2016 Jun 20. Cancer Chemother Pharmacol. 2016. PMID: 27324021 Free PMC article.
Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer.
Ohta H, Hayashi T, Murai S, Shiouchi H, Ando Y, Kumazawa S, Ito K, Ikeda Y, Matsuoka H, Maeda K, Kawada K, Yasuda K, Yamada S. Ohta H, et al. Among authors: ito k. Cancer Chemother Pharmacol. 2017 May;79(5):1021-1029. doi: 10.1007/s00280-017-3294-9. Epub 2017 Apr 8. Cancer Chemother Pharmacol. 2017. PMID: 28391355 Free PMC article.
12,196 results
You have reached the last available page of results. Please see the User Guide for more information.